Comparing the UK EQ-5D-3L and English EQ-5D-5L Value Sets

被引:73
作者
Mulhern, Brendan [1 ]
Feng, Yan [2 ]
Shah, Koonal [2 ]
Janssen, Mathieu F. [3 ]
Herdman, Michael [2 ]
van Hout, Ben [4 ]
Devlin, Nancy [2 ]
机构
[1] Univ Technol Sydney, Ctr Hlth Econ Res & Evaluat, 1-59 Quay St, Sydney, NSW 2000, Australia
[2] Southside, Off Hlth Econ, 105 Victoria St, London SW1E 6QT, England
[3] Erasmus Univ, Erasmus MC, Dept Med Psychol & Psychotherapy, POB 2040, NL-3000 CA Rotterdam, Netherlands
[4] Univ Sheffield, Hlth Econ & Decis Sci, Sch Hlth & Related Res, 30 Regent St, Sheffield S1 4DA, S Yorkshire, England
关键词
EUROQOL; VALUATION; VERSION; STATE;
D O I
10.1007/s40273-018-0628-3
中图分类号
F [经济];
学科分类号
02 ;
摘要
Three EQ-5D value sets (EQ-5D-3L, crosswalk, and EQ-5D-5L) are now available for cost-utility analysis in the UK and/or England. The value sets' characteristics differ, and it is important to assess the implications of these differences. The aim of this paper is to compare the three value sets. We carried out analysis comparing the predicted values from each value set, and investigated how differences in health on the descriptive system is reflected in the utility score by assessing the value of adjacent states. We also assessed differences in values using data from patients who completed both EQ-5D-3L and EQ-5D-5L. The distribution of the value sets systematically differed. EQ-5D-5L values were higher than EQ-5D-3L/crosswalk values. The overall range and difference between adjacent states was smaller. In the patient data, the EQ-5D-5L produced higher values across all conditions and there was some evidence that the value sets rank different health conditions in a similar severity order. There are important differences between the value sets. Due to the smaller range of EQ-5D-5L values, the possible change in quality-adjusted life years (QALYs) might be reduced, but they will apply to both control and intervention groups, and will depend on whether the gain is in quality of life, survival, or both. The increased sensitivity of EQ-5D-5L may also favour QALY gains even if the changes in utility are smaller. Further work should assess the impact of the different value sets on cost effectiveness by repeating the analysis on clinical trial data.
引用
收藏
页码:699 / 713
页数:15
相关论文
共 34 条
[1]   EQ-5D-5L versus EQ-5D-3L: The Impact on Cost Effectiveness in the United Kingdom. [J].
Alava, Monica Hernandez ;
Wailoo, Allan ;
Grimm, Sabine ;
Pudney, Stephen ;
Gomes, Manuel ;
Sadique, Zia ;
Meads, David ;
O'Dwyer, John ;
Barton, Garry ;
Irvine, Lisa .
VALUE IN HEALTH, 2018, 21 (01) :49-56
[2]  
[Anonymous], 2014, HLTH TECHNOL ASSESS
[3]  
[Anonymous], 2015, Guidelines for preparing submissions to the Pharmaceutical Benefits Advisory Committee (Version 4.5)
[4]  
[Anonymous], 2013, GUID METH TECHN APPR
[5]  
[Anonymous], 2011, CENS 2011
[6]  
[Anonymous], 2007, EQ 5D VALUE SETS INV
[7]  
Appleby J., 2015, Using Patient Reported Outcomes to Improve Health Care
[8]   STATISTICAL METHODS FOR ASSESSING AGREEMENT BETWEEN TWO METHODS OF CLINICAL MEASUREMENT [J].
BLAND, JM ;
ALTMAN, DG .
LANCET, 1986, 1 (8476) :307-310
[9]  
Brazier J, 2005, HEALTH ECON, V13, P873
[10]   EuroQol: The current state of play [J].
Brooks, R .
HEALTH POLICY, 1996, 37 (01) :53-72